Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells.
about
Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancerDown-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin.Peptide receptor targeting in cancer: the somatostatin paradigm.Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancerNeuroendocrine differentiation in castration-resistant prostate cancer: A case report.
P2860
Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Differential molecular mechani ...... in PC3 prostate cancer cells.
@en
Differential molecular mechani ...... in PC3 prostate cancer cells.
@nl
type
label
Differential molecular mechani ...... in PC3 prostate cancer cells.
@en
Differential molecular mechani ...... in PC3 prostate cancer cells.
@nl
prefLabel
Differential molecular mechani ...... in PC3 prostate cancer cells.
@en
Differential molecular mechani ...... in PC3 prostate cancer cells.
@nl
P2093
P1433
P1476
Differential molecular mechani ...... s in PC3 prostate cancer cells
@en
P2093
Federica Tonissi
Gerard Milano
Laura Lattanzio
Marco C Merlano
P304
P356
10.1097/CAD.0B013E328358D1DC
P577
2013-02-01T00:00:00Z